Saturday 11 April 2026

The Pharma Letter Podcast — Episode 34 — Is this a revolution in Alzheimer's?

Pharmaceutical
Simon Wentworth
12 June 2025

More on this story...

Biotechnology
Positive top-line Alzheimer’s disease data from NewAmsterdam
10 June 2025
Pharmaceutical
Dementia Discovery Fund takes total fundraising beyond $550 million
21 May 2025
Biotechnology
AriBio and Arcera sign $600 million licensing and supply agreements
11 June 2025


Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Boehringer hands CT-155 rights to Click in schizophrenia pivot
Pharmaceutical
Boehringer hands CT-155 rights to Click in schizophrenia pivot
10 April 2026
Biotechnology
Daiichi taps Imagene to sharpen cancer biomarker discovery
10 April 2026
Pharmaceutical
Annovis secures financing for buntanetap’s NDA submission
10 April 2026
Pharmaceutical
Tempus AI expands collaboration with Gilead
10 April 2026
Pharmaceutical
Medicines Australia firmly opposes US tariffs on pharmaceuticals
10 April 2026
Biotechnology
Alligator Bioscience links up with Unicancer on mitazalimab
10 April 2026
Biotechnology
Boehringer and BioNTech collaborate on SCLC trial of obrixtamig combo
10 April 2026


Company Spotlight

Fate Therapeutics
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.


More Features in Pharmaceutical

Boehringer hands CT-155 rights to Click in schizophrenia pivot
10 April 2026
Annovis secures financing for buntanetap’s NDA submission
10 April 2026
Tempus AI expands collaboration with Gilead
10 April 2026
Medicines Australia firmly opposes US tariffs on pharmaceuticals
10 April 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze